TA
ALLO icon

Teachers Advisors’s Allogene Therapeutics ALLO Stock Holding History

Teachers Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$9.02M Sell
311,844
-44,067
-12% -$1.28M 0.01% 1048
2018
Q4 		$9.59M Buy
+355,911
New +$9.46M 0.01% 951

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Teachers Advisors's ALLO Position: Q1 2019 in Review

Teachers Advisors reduced its Allogene Therapeutics (ALLO) stake by 12% in Q1 2019, selling an estimated $1.28M and leaving 311,844 shares worth $9.02M. The position accounts for 0.01% of the portfolio, ranked #1048.

Teachers Advisors first reported a position in ALLO in Q4 2018 and has held it in 2 quarters since. The position peaked at $9.59M in Q4 2018. 86 funds tracked by Wall St. Rank hold ALLO as of Q1 2019.

  • Teachers Advisors held 311,844 shares of Allogene Therapeutics worth $9.02M as of Q1 2019.
  • Teachers Advisors sold 44,067 Allogene Therapeutics shares in Q1 2019, an estimated $1.28M.
  • Allogene Therapeutics made up 0.01% of Teachers Advisors's portfolio in Q1 2019, its #1048 holding.
  • Teachers Advisors first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • Teachers Advisors's Allogene Therapeutics position peaked at $9.59M in Q4 2018.
  • 86 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2019.

Based on Teachers Advisors's 13F filing for Q1 2019, filed 14 May 2019.